Product Description
Nadolol is used alone or together with other medicines (such as hydrochlorothiazide) to treat high blood pressure (hypertension). This medicine is a beta-blocker. It works by affecting the response to nerve impulses in certain parts of the body, like the heart. As a result, the heart beats slower and decreases the blood pressure. When the blood pressure is lowered, the amount of blood and oxygen is increased to the heart . (Sourced from: https://www.mayoclinic.org/drugs-supplements/nadolol-oral-route/side-effects/drg-20071105?p=1)
Mechanisms of Action: ADRB1 Antagonist,ADRB2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Chile | Colombia | France | Germany | Greece | India | Ireland | Italy | Korea | New Zealand | Pakistan | Peru | Portugal | Slovenia | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Invion
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, New Zealand, Thailand, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Cognitive Dysfunction|Communicable Diseases|Dementia|Diabetic Retinopathy|Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Keratoconjunctivitis, Infectious|Lewy Body Dementia|Lewy Body Disease|Macular Edema|Movement Disorders|Parkinson's Disease|REM Sleep Behavior Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| INV-102-CS-004 | P2 |
Recruiting |
Diabetic Retinopathy|Macular Edema |
2025-08-01 |
|
| INV-102-CS-002 | P2 |
Completed |
Keratoconjunctivitis, Infectious|Communicable Diseases |
2024-08-22 |
|
| INV-102-CS-003 | P2 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes |
2024-07-03 |
|
| INV-102-CS-001 | P2 |
Completed |
Dry Eye Syndromes|Dry Eye Disease|Keratoconjunctivitis Sicca |
2023-05-02 |